Tonix Pharma Completes Acquisition of Two FDA-Approved, Marketed Migraine Products
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals Holding Corp. (TNXP) has completed the acquisition of two FDA-approved, marketed migraine products from Upsher-Smith Laboratories. The products, Zembrace SymTouch and Tosymra, generated sales of approximately $23 million in 2022.
July 03, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals has expanded its product portfolio with the acquisition of two migraine products. This could potentially increase the company's revenues, given the products' past sales performance.
The acquisition of two marketed products that have already generated significant sales is a positive development for Tonix Pharmaceuticals. This could potentially increase the company's revenues and profitability, which could have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100